---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125390"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:48:49.607170+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences Q3 net loss $21M; cash $174.4M; Phase 3 CoMpass authorized in Europe

## Summary
- Net loss $21.0M (Q3 2024) vs $18.5M YoY; cash $174.4M funds operations into 2H 2026.
- Phase 2 end-of-study: 80% tumor control, 90% visual acuity preservation in early-stage choroidal melanoma.
- Phase 3 CoMpass trial authorized to enroll in Europe; >100 patients pre-screened globally.
- Phase 1 NMIBC: 4/5 low-grade clinical complete responses; immune activation field effect observed.
- Appointed Sabine Brookman-May as SVP, Therapeutic Area Head Urologic Oncology.

## SEC filing metadata
- accession: 0000950170-24-125390
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017024125390/0000950170-24-125390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017024125390/aura-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125390
- JSON: https://secwatch.observer/filing/0000950170-24-125390.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125390.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.